Longitudinal Evaluation of DCE-MRI as an Early Indicator of Progression after Standard Therapy in Glioblastoma

被引:0
|
作者
Arevalo-Perez, Julio [1 ,2 ]
Trang, Andy [1 ]
Yllera-Contreras, Elena [1 ]
Yildirim, Onur [1 ,2 ]
Saha, Atin [1 ,2 ]
Young, Robert [1 ,2 ,3 ]
Lyo, John [1 ,2 ]
Peck, Kyung K. [1 ,4 ]
Holodny, Andrei I. [1 ,2 ,3 ,5 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10065 USA
[2] Cornell Univ, Weill Med Coll, Dept Radiol, 525 East 68th St, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, 1275 York Ave, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med Phys, 1275 York Ave, New York, NY 10065 USA
[5] Weill Cornell Grad Sch Med Sci, Dept Neurosci, 1300 York Ave, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
dynamic contrast-enhanced (DCE) perfusion MRI; maximum plasma volume Vp max; Ktrans; GBM; progression of disease; POD; APPARENT DIFFUSION-COEFFICIENT; PERFUSION MRI; PARAMETERS; TUMOR; RADIOTHERAPY; VOLUME;
D O I
10.3390/cancers16101839
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Purpose: Distinguishing treatment-induced imaging changes from progressive disease has important implications for avoiding inappropriate discontinuation of a treatment. Our goal in this study is to evaluate the utility of dynamic contrast-enhanced (DCE) perfusion MRI as a biomarker for the early detection of progression. We hypothesize that DCE-MRI may have the potential as an early predictor for the progression of disease in GBM patients when compared to the current standard of conventional MRI. Methods: We identified 26 patients from 2011 to 2023 with newly diagnosed primary glioblastoma by histopathology and gross or subtotal resection of the tumor. Then, we classified them into two groups: patients with progression of disease (POD) confirmed by pathology or change in chemotherapy and patients with stable disease without evidence of progression or need for therapy change. Finally, at least three DCE-MRI scans were performed prior to POD for the progression cohort, and three consecutive DCE-MRI scans were performed for those with stable disease. The volume of interest (VOI) was delineated by a neuroradiologist to measure the maximum values for Ktrans and plasma volume (Vp). A Friedman test was conducted to evaluate the statistical significance of the parameter changes between scans. Results: The mean interval between subsequent scans was 57.94 days, with POD-1 representing the first scan prior to POD and POD-3 representing the third scan. The normalized maximum Vp values for POD-3, POD-2, and POD-1 are 1.40, 1.86, and 3.24, respectively (FS = 18.00, p = 0.0001). It demonstrates that Vp max values are progressively increasing in the three scans prior to POD when measured by routine MRI scans. The normalized maximum Ktrans values for POD-1, POD-2, and POD-3 are 0.51, 0.09, and 0.51, respectively (FS = 1.13, p < 0.57). Conclusions: Our analysis of the longitudinal scans leading up to POD significantly correlated with increasing plasma volume (Vp). A longitudinal study for tumor perfusion change demonstrated that DCE perfusion could be utilized as an early predictor of tumor progression.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
    O'Connor, J. P. B.
    Jackson, A.
    Parker, G. J. M.
    Jayson, G. C.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (02) : 189 - 195
  • [22] Evaluation of a Voxelized Model Based on DCE-MRI for Tracer Transport in Tumor
    Magdoom, K. N.
    Pishko, Gregory L.
    Kim, Jung Hwan
    Sarntinoranont, Malisa
    [J]. JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME, 2012, 134 (09):
  • [23] DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
    J P B O'Connor
    A Jackson
    G J M Parker
    G C Jayson
    [J]. British Journal of Cancer, 2007, 96 : 189 - 195
  • [24] Evaluation of Different Tracer Kinetic Models in DCE-MRI of Rectal Cancer
    Sansone, M.
    Fusco, R.
    Aprile, F.
    Petrillo, M.
    Petrillo, A.
    Siani, A.
    Bracale, U.
    [J]. WORLD CONGRESS ON MEDICAL PHYSICS AND BIOMEDICAL ENGINEERING, VOL 25, PT 2 - DIAGNOSTIC IMAGING, 2009, 25 : 34 - 37
  • [25] A new CAD system for the evaluation of kidney diseases using DCE-MRI
    El-Baz, Ayman
    Fahmi, Rachid
    Yuksel, Seniha
    Farag, Aly A.
    Miller, William
    El-Ghar, Mohamed A.
    Eldiasty, Tarek
    [J]. MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2006, PT 2, 2006, 4191 : 446 - 453
  • [26] Combination of IVIM with DCE-MRI for diagnostic and prognostic evaluation of breast cancer
    Zhang, Jing
    Zheng, Yurong
    Li, Li
    Wang, Rui
    Jiang, Weilong
    Ai, Kai
    Gan, Tiejun
    Wang, Pengfei
    [J]. MAGNETIC RESONANCE IMAGING, 2024, 113
  • [27] Tumor modifications recorded with IVIM and DCE-MRI after Neoadjuvant radiotherapy
    Lallemand, F.
    Leroi, N.
    Bahri, M.
    Balteau, E.
    Noel, A.
    Coucke, P.
    Plenevaux, A.
    Martinive, P.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S284 - S285
  • [28] Quantification of Tumor Changes during Neoadjuvant Chemotherapy with Longitudinal Breast DCE-MRI Registration
    Wu, Jia
    Ou, Yangming
    Weinstein, Susan P.
    Conant, Emily F.
    Yu, Ning
    Hoshmand, Vahid
    Keller, Brad
    Ashraf, Ahmed B.
    Rosen, Mark
    DeMichele, Angela
    Davatzikos, Christos
    Kontos, Despina
    [J]. MEDICAL IMAGING 2015: COMPUTER-AIDED DIAGNOSIS, 2015, 9414
  • [29] DCE-MRI biomarkers of tumor cytoablation efficacy and subsequent recurrence in an orthotopic, preclinical glioblastoma model
    Nagaraja, T.
    Bartlett, S.
    Cabral, G.
    Farmer, K.
    Avritt, F.
    Acharya, P.
    Valadie, O.
    Knight, R.
    Brown, S.
    Ewing, J.
    Lee, I.
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2022, 42 (1_SUPPL): : 187 - 187
  • [30] RETRACTED: Changes of DCE-MRI Parameters in Patients with Rheumatoid Arthritis before and after Therapy and Their Value for the Efficacy Evaluation of Patients (Retracted Article)
    Chen, Danguo
    He, Shengquan
    [J]. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021